1. Male or female subjects, 18-65 years of age at the time of signing informed consent;

2. At screening and random visit, 28.0 ≤BMI≤ 40.0 kg/m2;

3. Diet and exercise control for at least 3 months before screening and random visit, and less than 5 % self-reported change within the last 3 months.

4. Able and willing to provide a written informed consent

1. Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit;

2. Uncontrollable hypertension;

3. PHQ-9 score ≥15;

4. History of diabetes;

5. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;

6. Any organ-system malignancies developed within 5 years except for cured local basal cell cancer of the skin and in-situ cancer of the cervix;

7. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;

8. Use of any medication or treatment that may have caused significant weight change within 2 months;

9. History of bariatric surgery;

10. history of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening;

11. Surgery is planned during the trial;

12. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method;

13. Researchers and relevant staff of the research Centre or other people directly involved in the implementation of the programme, and their immediate family members.